Michel Demonget

Synthelis SAS manufactures membrane proteins. It specializes in the production, purification, and characterization of custom membrane proteins. The firm's services Membrane Protein (MP) expression, proteoliposomes, MP in detergents, feasibility study, and quality controls. Synthelis' technology enables the embedding of membrane proteins in liposomes directly during the translation step, allowing the production of active ready-to-use proteoliposomes. The company was founded by Bruno Tillier and Jean-Luc Lenormand in January 2011 and is headquartered in La Tronche, France.

International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.

Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD.

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

Texcell SA is a contract research organization that provides services for viral clearances, viral safety testing, and the manufacture of GMP cell banks to pharmaceutical companies and bioventures. The private company is based in France and has subsidiaries in various locations, including the United States. The French company has offices and laboratories in various locations around the world, including France, the United States, and Japan. The company's capabilities include in vivo, in vitro, toxicology, immunotoxicity, and immunogenicity testing, as well as CGMP cell banking and preparation of fully characterized virus stocks. Texcell has recently strengthened its activities to face the growing demand for tests related to COVID-19. The company is developing new innovative tests and new protocols in molecular biology and immunology.

ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada.

Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.

Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France.

The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024.

Michel Greco SA provides postal, courier, and express services. The private company is based in Luxembourg, Luxembourg. The Luxembourger company was founded in 1987 by Michel Gréco.